Table 2. Correlation between baseline characteristics and VEGF-A and VEGFR-2 concentrations (all arms pooled).
| |
VEGF-A |
VEGFR-2 |
||||
|---|---|---|---|---|---|---|
| Low, n (%) (n=197) | High, n (%) (n=196) | Interaction P-value | Low, n (%) (n=197) | High, n (%) (n=196) | Interaction P-value | |
|
Age, years | ||||||
| <65 | 157 (80) | 156 (80) | 1.0000 | 149 (76) | 164 (84) | 0.0599 |
| ⩾65 |
40 (20) |
40 (20) |
|
48 (24) |
32 (16) |
|
|
ECOG PS | ||||||
| 0 | 125 (63) | 120 (61) | 0.6739 | 118 (60) | 127 (65) | 0.4616 |
| 1 | 68 (35) | 74 (38) | 74 (38) | 68 (35) | ||
| 2 |
1 (<1) |
0 |
|
1 (<1) |
0 |
|
|
Disease-free interval | ||||||
| ⩽median | 67 (34) | 70 (36) | 0.8320 | 70 (36) | 67 (34) | 0.9156 |
| >median |
128 (65) |
125 (64) |
|
127 (64) |
126 (64) |
|
|
ER status | ||||||
| Negative | 49 (25) | 54 (28) | 0.5662 | 56 (28) | 47 (24) | 0.3604 |
| Positive |
148 (75) |
140 (71) |
|
141 (72) |
147 (75) |
|
|
ER/PgR combined | ||||||
| Negative | 40 (20) | 40 (20) | 1.0000 | 48 (24) | 32 (16) | 0.0600 |
| Positive |
157 (80) |
155 (79) |
|
149 (76) |
163 (83) |
|
|
No. of metastatic sites | ||||||
| ⩾3 | 87 (44) | 95 (48) | 0.5425 | 94 (48) | 88 (45) | 0.6119 |
| <3 | 106 (54) | 101 (52) | 101 (51) | 106 (54) | ||
Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; ER=oestrogen receptor; PgR=progesterone receptor; VEGF-A=vascular endothelial growth factor A; VEGFR-2=vascular endothelial growth factor receptor 2.